| Date | Title | Description |
| 17.09.2026 | Hologic Leads U.S. Adoption as Breast Cancer Diagnostics Market Rises from USD 5,878.0 million in 2025 to USD 12,451.97 million by 2036 at 6.9% CAGR | ROCKVILLE, MD /Sept 17, 2026 – According to Fact.MR estimates, the breast cancer diagnostics market stood at USD 5,878.0 million in 2025. The market is projected to reach USD 6,389.41 million in 2026 and climb to USD 12,451.97 million by 20... |
| 03.09.2026 | ASEAN Rapid Diagnostic Test Market to Reach USD 1.36 Billion by 2030 | The ASEAN Rapid Diagnostic Test Market is valued at an estimated USD 1.08 billion in 2025 and is projected to reach USD 1.36 billion by 2030, registering a CAGR of 4.7% during the forecast period. Market growth is being driven by the rising... |
| 28.08.2026 | Breast Cancer Liquid Biopsy Market Trends: Precision Oncology and Minimally Invasive Diagnostics Driving Growth | The breast cancer liquid biopsy market is emerging as a promising segment of precision oncology as healthcare providers increasingly seek minimally invasive approaches for cancer detection, monitoring, and treatment planning. Liquid biopsy ... |
| 28.08.2026 | Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers | TSY-110 is positioned to become the first biosimilar alternative to Roche's Kadcyla® (ado-trastuzumab emtansine) in major regulated markets.
TAIPEI, Aug. 28, 2026 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (TWSE: 6838), today announced t... |
| 28.08.2026 | China's DualityBio Rises After Forging USD1 Billion Cancer Drug Tie-Up With Roche Unit | (Yicai) Aug. 28 -- Shares of Duality Biotherapeutics rose after it said it has agreed to co‑develop next‑generation antibody‑drug conjugates for multiple oncology indications with Genentech, a subsidiary of Switzerland's Roche, based on the... |
| 28.08.2026 | DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Generation ADCs Built on DualityBio's DUPAC Novel-Payload Platform | Collaboration leverages DualityBio's proprietary DUPAC payload platform and early global clinical development capabilities, with Genentech assuming further clinical development and global commercialization
DUPAC, one of the DualityBio's fou... |
| 27.08.2026 | Adaptyv Raises $40 Million Series A As Automated Biology Lab Throughput Grows More Than 5x | Adaptyv has raised $40 million in Series A funding to expand its automated laboratory infrastructure for agentic biology. Highland Europe led the round, with existing investors ACE Ventures, byFounders and Y Combinator increasing their inve... |
| 26.08.2026 | Adaptyv raises $40M to build automated lab for agentic biology |
Adaptyv Biosystems has developed an automated wet lab for rapid experimental validation of newly designed proteins, while drastically reducing the costs per protein. Powered by artificial intelligence, this full-stack platform makes it eas... |
| 25.08.2026 | Innovent Announces 2026 Interim Results and Business Updates | Transforming from Regional Leader to Global Premier:
A Clear Strategic Path for Growth and Globalization
SAN FRANCISCO and SUZHOU, China, Aug. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biophar... |
| 24.08.2026 | Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy | HM17321, a proprietary UCN2 (urocortin-2) analog, is being developed as a treatment for chronic-weight management and associated conditions, including obesity
Total deal value of up to $2.3 billion, including upfront, milestone payments and... |
| 24.08.2026 | Genentech Pays $190M for Obesity Drug Built to Preserve Muscle GLP-1 Drugs Erode | By Benjamin Eddie
Published: Aug 24 2026, 2:52 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 21.08.2026 | lab on a chip technology Market to Reach USD 21.36 Billion by 2030 | The global lab on a chip technology Market is projected to grow from USD 14.01 billion in 2025 to USD 21.36 billion by 2030, registering a CAGR of 8.8% during the forecast period. Market growth is being driven by increasing demand for high-... |
| 21.08.2026 | CNA Explains: What we know about the Moderna, Merck breakthrough cancer vaccine | Listen
5 min
New: You can now listen to articles.
This audio is generated by an AI tool.
Drugmakers Moderna and Merck have scored a breakthrough with a personalised cancer vaccine that doctors hope could eventually work against many types o... |
| 21.08.2026 | Immunoassay Testing Market to Reach USD 47.7 Billion by 2030 | The global Immunoassay testing Market is projected to grow from USD 35.5 billion in 2025 to USD 47.7 billion by 2030, registering a CAGR of 6.1% during the forecast period. Market expansion is being driven by the growing burden of chronic a... |
| 19.08.2026 | Российская фармкомпания стала лидером по выплатам врачам и медорганизациям | Российская фармкомпания стала лидером по выплатам врачам и медорганизациям Иностранные игроки все меньше тратят на исследования
«Р-Фарм» потратил на выплаты врачам и организациям в 2025 году 2,2 млрд руб., больше, чем любой другой член Ассо... |
| 14.08.2026 | Pharmaceuticals Market Trends: Innovation, Rising Healthcare Demand, and Advanced Therapies Driving Growth | The pharmaceuticals market is witnessing strong growth as rising healthcare needs, increasing disease prevalence, expanding access to medicines, and continuous innovation in drug development drive global demand. Pharmaceutical products play... |
| 12.08.2026 | Silent Cancer Therapeutics Market Size to Reach USD 36.52 Billion by 2035, Driven by Precision Oncology and Advanced Cancer Therapies | Overview
According to DataM Intelligence, the global silent cancer therapeutics market size was valued at USD 15.86 billion in 2025 and is forecast to reach USD 36.52 billion by 2035, expanding at a CAGR of 8.7% during 2026 to 2035. The mar... |
| 06.08.2026 | Manufacturing Jobs Flock to the U.S. Thanks to President Trump’s America First Economic Agenda | With President Trump’s economic agenda taking effect, the United States is seeing an economic revival across our manufacturing industry. July saw the strongest expansion in domestic manufacturing activity in more than four years, marking se... |
| 06.08.2026 | Prothena Reports Second Quarter 2026 Financial Results and Business Highlights | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the second quarter and... |
| 06.08.2026 | - | Roche's LightCycler® 480
Roche's LIghtCycler® PRO
"Understanding disease outbreaks and how they spread can have a huge impact on public health," said Dan Malarek, President and CEO, Roche Diagnostics North America. "Our robus... |
| 29.07.2026 | AbbVie Announces Availability of ELAHERE® (mirvetuximab soravtansine) in Singapore for the Treatment of Platinum-Resistant Ovarian Cancer | ELAHERE is the first and only antibody-drug conjugate (ADC) therapy approved specifically for patients with folate receptor alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian cancer, fallopian tube or primary peri... |
| 24.07.2026 | ArkBio Completes all Cohort Dosing in Australian Phase I Trial with Influenza AFC Drug AK0406 | SHANGHAI, July 24, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial with AK0406, a novel long-acting ant... |
| 17.07.2026 | Tiina Frazer appointed Senior Vice President, Brand, Marketing and Communications at Nokian Tyres and a member of the Nokian Tyres Management Team | Tiina Frazer appointed Senior Vice President, Brand, Marketing and Communications at Nokian Tyres and a member of the Nokian Tyres Management Team
Fri, Jul 17, 2026 12:30 CET Report this content
Nokian Tyres plc Stock Exchange Release July ... |
| 15.07.2026 | Минздрав впервые зарегистрировал препарат по итогам инспекции за рубежом | Минздрав впервые зарегистрировал препарат по итогам инспекции за рубежом Eisai получила регудостоверение, хотя не проводила клинисследований в России
Японская фармкомпания Eisai 1 июля получила регудостоверение на свой новый препарат против... |
| 15.07.2026 | Biochips Market to Reach $21.36 Billion by 2030 | The global biochips market is projected to grow from USD 14.01 billion in 2025 to USD 21.36 billion by 2030, at a CAGR of 8.8% during the forecast period. Market growth is fueled by increasing demand for faster, more accurate, and cost-effe... |
| 14.07.2026 | Converging at BIO, ACROBiosystems Connects Emerging Innovation Assets with Global Strategic Opportunities | SAN DIEGO, July 14, 2026 /PRNewswire/ -- Ahead of the BIO International Convention, BIOSeedin Summer Innovation Partnering Summit was successfully held at Wyndham San Diego Bayside, California. Hosted by bioSeedin, the summit's discussion t... |
| 14.07.2026 | Body Fluid Analysis Market to Reach $3.65 Billion by 2031 | The global body fluid analysis market is projected to grow from USD 2.62 billion in 2026 to USD 3.65 billion by 2031, at a CAGR of 6.9% during the forecast period. Market growth is primarily driven by the increasing global incidence of infe... |
| 13.07.2026 | Deep-tech and biotech startups strengthen their leadership teams |
Lausanne-based Neural Concept, an EPFL spin-off founded in 2018 developing AI software for engineering, has appointed Brett Chouinard as Chairman of the Board of Directors, Pietro Cervellera as Chief Revenue Officer and Alex Read as Senior... |
| 13.07.2026 | Molecular Cytogenetics Market to Reach $1.43 Billion by 2030 | The global molecular cytogenetics market is projected to grow from USD 1.02 billion in 2025 to USD 1.43 billion by 2030, at a CAGR of 7.1% during the forecast period. Market growth is primarily driven by the increasing incidence of cancer a... |
| 10.07.2026 | ABB Robotics collaborates with Roche to bring physical AI to laboratories | ABB Robotics collaborates with Roche to bring physical AI to laboratories
Fri, Jul 10, 2026 11:43 CET Report this content
Zurich, Switzerland, July 8, 2026
ABB Robotics collaborates with Roche to bring physical AI to laboratories Agreement ... |
| 09.07.2026 | Global In Vitro Diagnostic (IVD) Products Market Share, Growth Drivers, Trends, Overall Sales and Demand Forecast To 2032 | The Global In Vitro Diagnostic (IVD) Products Market is witnessing remarkable growth as healthcare systems worldwide prioritize early disease detection, personalized treatment, and preventive care. In vitro diagnostic products have become a... |
| 09.07.2026 | Immunotherapy Drugs Market to Reach $580.6 Billion by 2029 | The global Immunotherapy drugs market is projected to grow from USD 285.3 billion in 2024 to USD 580.6 billion by 2029, at a robust CAGR of 15.3% during the forecast period. Market growth is driven by advancements in antibody engineering te... |
| 07.07.2026 | Could Insulin Patch Pumps Become the Future of Diabetes Care? Market Outlook Through 2034 | Managing diabetes is becoming increasingly technology-driven as healthcare providers shift from conventional insulin delivery methods toward connected and patient-friendly solutions. Among these innovations, insulin patch pumps are gaining ... |
| 07.07.2026 | Molecular Diagnostics Market to Reach $30.74 Billion by 2030 | The global molecular diagnostics market is estimated at USD 19.48 billion in 2025 and is projected to reach USD 30.74 billion by 2030, growing at a CAGR of 9.6% during the forecast period. Market expansion is driven by increasing investment... |
| 07.07.2026 | BIOHK2026 (Hong Kong International Biotechnology Conference and Exhibition), 9-12 September, Hong Kong - Connecting Global Leaders in Biotechnology | Seeking biotech investment, breakthrough innovations, or a strategic gateway to the Asia-Pacific? The answers await in Hong Kong this September.
HONG KONG, July 7, 2026 /PRNewswire/ -- The 5th Hong Kong International Biotechnology Conferenc... |
| 06.07.2026 | Immunoassay Market to Reach $47.7 Billion by 2030 | The global Immunoassay market is projected to grow from USD 35.5 billion in 2025 to USD 47.7 billion by 2030, at a CAGR of 6.1% during the forecast period. Market growth is primarily driven by the expanding elderly population and the increa... |
| 06.07.2026 | Онкопациенты выше всего оценили репутацию Roche, AstraZeneca и Novartis | Онкопациенты выше всего оценили репутацию Roche, AstraZeneca и Novartis
Исследовательская компания PatientView представила ежегодный рейтинг репутации фармкомпаний в онкологии. В нем 505 пациентских организаций из разных стран, работающих в... |
| 03.07.2026 | Sky Labs Showcases 'CART BP pro' for Potential Use in Drug Clinical Trials on Global Stage | BASEL, Switzerland and SEOUL, South Korea, July 3, 2026 /PRNewswire/ -- Sky Labs (CEO Jack Byunghwan Lee) announced on the 2nd that it introduced its data platform business at the 9th Digital Biomarkers in Clinical Trials Summit in Basel, S... |
| 03.07.2026 | Nona Biosciences Appoints Dr. Peng Wang as Chief Operating Officer to Advance Platform Capabilities and Drive Operational Excellence | CAMBRIDGE, Mass., July 3, 2026 /PRNewswire/ -- Nona Biosciences ("Nona" or the "Company"), a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, today announced the ap... |
| 02.07.2026 | Biotech and Food companies strengthen management teams on the business side |
Basel-based pharma company Idorsia has appointed Roland Wandeler as CEO, effective October 1, 2026. He will succeed Jean-Paul Clozel, who has been serving as ad interim CEO since March 2026 and will continue as Chairman of the Board of Dir... |
| 01.07.2026 | EIB Grants Orano €125 Million Loan To Finance Orano Med Innovations And Infrastructure | The European Investment Bank and Orano announced the signing of a €125 million credit line to finance the development of Orano Med and its industrial infrastructure.
The financing will notably support the construction of the Advanced Thoriu... |
| 30.06.2026 | Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China | SAN FRANCISCO and SUZHOU, China, June 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for... |
| 19.06.2026 | Gero Raises $17 Million To Slow Aging | Gero announced it has raised $17 million in new financing, bringing its total equity funding to $34 million. The company is developing medicines designed to slow aging and treat age-related diseases by combining longitudinal human data, AI,... |
| 19.06.2026 | U.S. opens tariff probe targeting Germany’s drug pricing policies | The U.S. said the probe will examine whether “persistent underpayment” for medicines by Germany is discriminatory.
“President Trump has made clear that American patients should not be shouldering a disproportionate share of global pharmaceu... |
| 19.06.2026 | What this biotech’s volatile stock price tells you about the weight loss market right now | Recent setbacks for Danish biotech Zealand Pharma forced analysts to rethink the company’s obesity strategy
While its drug survodutide disappointed in terms of dropout rates, analysts remain upbeat on its amylin-based drug petrelintide
An e... |
| 18.06.2026 | Neuron23 Receives $2.5 Million Grant From The Michael J. Fox Foundation To Expand Phase 2 Parkinson’s Trial | Neuron23, a clinical-stage biotechnology company developing precision medicines for Parkinson’s disease, announced it received a $2.5 million grant from The Michael J. Fox Foundation for Parkinson’s Research to support the expansion of its ... |
| 13.06.2026 | Switzerland is voting on whether to cap its population at 10 million. Here’s what to know | Switzerland will hold a referendum on Sunday on whether to cap its population at 10 million people.
If the measure is passed, Swiss officials will have to roll out measures to curb population growth until 2050.
Businesses have warned that l... |
| 13.06.2026 | Drugmakers race to find a place in the next wave of obesity drugs | Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine.
Drugmakers pitched doctors and investors on their future drugs at the recent American Diabetes Association (ADA) Scient... |
| 12.06.2026 | Harbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific Advisor | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 12, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody ther... |
| 10.06.2026 | PhoreMost announces lead oncology programme and appoints Chief Medical Officer to support clinical entry | Next-generation small molecule microtubule targeting agent, PMC-001, progressing towards Phase 1
Comprehensive preclinical data package demonstrates differentiating oral activity and CNS penetration, unlocking treatment of primary and secon... |
| 10.06.2026 | SOPHiA GENETICS Confirms Leadership Transition Ahead of 2026 Annual General Meeting | Ross Muken to assume the role of Chief Executive Officer effective July 1, 2026; Co-founder Dr. Jurgi Camblong nominated for election as Chairman of the Board
BOSTON and ROLLE, Switzerland, June 10, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nas... |
| 09.06.2026 | R1.2-billion win for South African innovation agency | Technology Innovation Agency CEO Titus Mathe
Just months after securing US$72.9-million (R1.2-billion) in a landmark settlement with shareholders of former local biotech Kapa Biosystems, the Technology Innovation Agency (TIA) this week reve... |
| 08.06.2026 | 2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline | SAN FRANCISCO and SUZHOU, China, June 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for t... |
| 04.06.2026 | World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer an... | SAN FRANCISCO and SUZHOU, China, June 4, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for t... |
| 01.06.2026 | 2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy... | After long-term follow-up, IBI363 monotherapy demonstrated strong overall survival (OS) with a long tail effect in IO-resistant squamous NSCLC and adenoNSCLC
IBI363 has entered a global Phase 3 clinical study (MarsLight-11) for IO-resistant... |
| 01.06.2026 | 2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC | IBI363 in combination with chemotherapy demonstrated encouraging efficacy signals and manageable safety in the first-line treatment of NSCLC with PD-L1 negative or low expression. The 3→1.5 mg/kg dose group (n=22) showed ORR of 86.4%, confi... |
| 31.05.2026 | A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China | An experimental lung cancer drug from Akeso and Summit Therapeutics improved survival in the Harmoni-6 Phase 3 trial conducted in China, according to results being presented at the American Society of Clinical Oncology annual meeting.
Calle... |
| 29.05.2026 | Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines | SAN FRANCISCO and NEW YORK, and SUZHOU, China, May 29, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK) and Pfizer Inc. (NYSE: PFE), today announced the companies have entered into a strategic global licensing and collaboration agre... |
| 27.05.2026 | AI firm Visium secures funds to scale across Europe and US |
Founded in 2018 in Lausanne, Visium provides AI and data services to companies in regulated industries, primarily life sciences and specialty chemicals. The company runs a dual model that combines consulting with software products, includi... |
| 25.05.2026 | Stilta Closes $10.5 Million For Agentic AI Patent Litigation Platform | Stilta, an AI company focused on patent litigation and intelligence, announced $10.5 million in funding led by Andreessen Horowitz, with participation from Y Combinator and founders and operators from leading AI companies including Sana, Le... |
| 19.05.2026 | Innovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences | SAN FRANCISCO and SUZHOU, China, May 19, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for t... |
| 13.05.2026 | Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions | SAN FRANCISCO and SUZHOU, China, May 13, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for t... |
| 07.05.2026 | Roche Enters Into a Definitive Merger Agreement to Acquire Pathai to Transform Ai-Driven Diagnostics | announced that it has entered into a definitive merger agreement to acquire PathAI, a US-based company in digital pathology and AI-powered technology for pathology laboratories and the biopharma industry. This acquisition builds on the succ... |
| 07.05.2026 | Prothena Reports First Quarter 2026 Financial Results and Business Highlights | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the first quarter of 2... |
| 06.05.2026 | Roche Acquires PathAI to Automate Cancer Diagnostics in $1B Deal
The $1B Digital Pathology Consolidation: Roche Agrees to Acquire PathAI to Automate Cancer Diagnostics | What You Should Know
Global healthcare leader Roche has entered into a definitive merger agreement to acquire US-based digital pathology pioneer PathAI for an upfront purchase price of $750M, with up to $300M in additional milestone payment... |
| 27.04.2026 | AI Drives Europe's Tech Boom: Billions Flow to Security, Cloud, and Next-Gen Innovation | European tech funding surged past €632 million. AI innovation drives significant investment. Cloudsmith secured $72M for AI software supply chain security. Verda raised $117M for AI cloud infrastructure. Acquisitions are robust, including A... |
| 24.04.2026 | Verda raises $117M, Aleph Alpha to be acquired, and solving the quantum bottleneck | This week, we tracked more than 65 tech funding deals worth over €632 million and over 5 exits, M&A transactions, rumours, and related news stories across Europe.
If email is more your thing, you can always subscribe to our newsletter a... |
| 24.04.2026 | Ferrosa Therapeutics: $3.5 Million Seed Financing For Bispecific Antibody Targeting Anemia Of Inflammation | Ferrosa Therapeutics AG, a Swiss biotechnology company focused on treating anemia of inflammation, announced a $3.5 million seed financing round led by Forty51 Ventures. The funding will support the advancement of the company’s first-in-cla... |
| 17.04.2026 | World Hemophilia Day 2026 - April 17, 2026 - "Diagnosis: First step to care." | MONTREAL, April 17, 2026 /PRNewswire/ -- On April 17, 2026, the global inherited bleeding disorders community will come together on World Hemophilia Day to advocate for all inherited bleeding disorders. This year's theme of "Diagnosis:... |
| 09.04.2026 | AI Pioneers Unite to Launch the Shared AI License Foundation to Advance Foundation Model Innovation | A new coalition of technology and innovation leaders has launched the Shared AI License Foundation (SAIL), the first organization dedicated to safeguarding AI innovation through a collaborative patent network. This initiative, led by foundi... |
| 06.04.2026 | Biotech Firm Gets a New Leader
New chief chosen | - |
| 01.04.2026 | Abbisko Therapeutics' FGFR4 Inhibitor Irpagratinib Granted Orphan Drug Designation by EMA for Hepatocellular Carcinoma | SHANGHAI, April 1, 2026 /PRNewswire/ -- 31 March 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256) announced that its independently developed, highly selective, oral small-molecule FGFR4 inh... |
| 31.03.2026 | Zürich-based Starmind acquired by US AI platform company Capacity |
For years, companies have invested in documenting knowledge across wikis, intranets, and knowledge bases. With the rise of generative AI, this documented knowledge has become more accessible than ever. Yet a fundamental problem remains: a ... |
| 30.03.2026 | Qyuns Therapeutics-B (02509) 2025 Revenue Surges Over 4-Fold; Adjusted Profit Reaches Approximately RMB356 Million, Turning a Profit Year-on-Year | TAIZHOU, China, March 30, 2026 /PRNewswire/ -- Qyuns Therapeutics-B (02509) announced its 2025 annual results. Revenue amounted to approximately RMB807 million, representing a 4.08-fold year-on-year increase. Gross profit reached approximat... |
| 30.03.2026 | Роскошный отель на Луне и роботы-пастухи: что показали самые безумные стартапы на YC Demo Day | Зимняя сессия стартап-акселератора Y Combinator 2026 года показала резкий рост стоимости таких предприятий. Базовая оценка компаний на посевной стадии удвоилась и достигла $30 млн. Отдельные проекты закрывали сделки с оценкой в $100 млн. Но... |
| 27.03.2026 | AstraZeneca stock jumps after surprise trial win for lung disease drug where rivals have failed | Britain’s most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials.
The respiratory treatment Tozorakimab, reduced flare-ups of chronic obstructive pulmonary disease in both former s... |
| 21.03.2026 | Candex Secures $40M+ HSBC Investment for Global Tail Spend Dominance | Candex closed over $40M in Series C extension funding. Strategic investment came from HSBC. Total funding now surpasses $120M. This capital targets massive global infrastructure growth. Expansion into Asia is a key focus. Platform capabilit... |
| 18.03.2026 | Mankind Pharma acquires Roche’s Rivotril brand for India, bolsters CNS presence | - |
| 18.03.2026 | Breakthrough at 2026 AACR! Senhwa Biosciences' CX-5461 Enters the Field of Photodynamic Therapy, Opening a New Indication Strategy | TAIPEI and SAN DIEGO, March 18, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage company focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announce... |
| 17.03.2026 | Roche Launches NVIDIA AI Factory to Accelerate the Development of New Therapeutics and Diagnostics Solutions | Roche announced that an expansion of its global AI infrastructure, deploying a large-scale AI factory powered by a full stack of the latest-generation NVIDIA accelerated computing and AI. Featuring 2,176 high-performance GPUs on premises ac... |
| 17.03.2026 | Candex Extends Series C to $40M+ with Strategic Investment from HSBC | Candex, a NYC-based vendor-management and tail-spend-solutions provider for global enterprises, extended its Series C funding to over $40M with a strategic investment from HSBC.
The raise brought the total funding to over $120M and added HS... |
| 17.03.2026 | Roche ramps up AI computing capacity with Nvidia chip expansion | BERLIN, March 16 : Swiss drugmaker Roche said on Monday it had expanded its artificial intelligence computing capacity with more than 2,100 Nvidia chips to support drug and diagnostics development.
Roche said the additional hardware would s... |
| 17.03.2026 | Candex: $40+ Million Series C Extension Raised To Scale Tail-Spend Management Platform | Candex, a technology-based vendor management platform focused on simplifying enterprise tail spend, has extended its Series C funding round to more than $40 million with a strategic investment from HSBC, bringing total funding to over $120 ... |
| 16.03.2026 | Nvidia launches enterprise AI agent platform with Adobe, Salesforce, SAP among 17 adopters at GTC 2026 | Jensen Huang walked onto the GTC stage Monday wearing his trademark leather jacket and carrying, as it turned out, the blueprints for a new kind of monopoly.
The Nvidia CEO unveiled the Agent Toolkit, an open-source platform for building au... |
| 14.03.2026 | ORO Labs Secures $100M to Revolutionize Enterprise AI Procurement | ORO Labs, an AI-driven procurement orchestration leader, secured $100 million in Series C funding. This capital injection follows a year of 300% revenue growth. The platform modernizes enterprise procurement. It streamlines complex global s... |
| 13.03.2026 | These stocks will benefit from AI and an aging population, Jefferies says. They also pay dividends | - |
| 13.03.2026 | Biophytis-LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics | Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies
This partnership will generate revenue through:
A computational longevity platform, including unique curated datas... |
| 12.03.2026 | ORO Labs raises $100M to expand procurement orchestration platform
Send us a News Tip
EXTRACT THE SIGNAL FROM THE NOISE
Cookies | Procurement orchestration platform company ORO Labs Inc. announced today that it has raised $100 million in new funding to accelerate its expansion, further develop its product and scale up customer success and deployment worldwide.
Founded... |
| 12.03.2026 | Dividend stocks are going gangbusters in 2026. Here’s what investors are doing with the extra cash | - |
| 10.03.2026 | Bright spots in tackling AMRs, but drug-resistance outpaces pharma industry efforts: Report | - |
| 06.03.2026 | Zealand’s stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the ‘weight loss Olympics’ | Shares of Danish drugmaker Zealand Pharma fell more than 35% after trial patients lost less weight than expected with its experimental medicine.
CEO Adam Steensberg told CNBC that, in the real world, Zealand’s drug offers massive potential ... |
| 03.03.2026 | Global Forum Head Ousted Over Epstein Links | Borge Brende, World Economic Forum CEO, resigned under pressure. His departure followed intense scrutiny over past connections with convicted sex offender Jeffrey Epstein. An independent review found no new revelations beyond previously dis... |
| 03.03.2026 | Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform | NEW YORK, March 3, 2026 /PRNewswire/ -- Royalty Pharma plc (Nasdaq: RPRX) announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company's royalty ... |
| 02.03.2026 | Emcure in pact with Roche to distribute select nephrology and transplant medicines | - |
| 27.02.2026 | BreezeBio: $60 Million Series B Raised To Advance Precision Genetic Medicines Pipeline | BreezeBio, formerly known as GenEdit, has closed $60 million in Series B financing to advance its first internal therapeutic programs toward the clinic and expand its NanoGalaxy delivery platform.
The South San Francisco-based biotechnology... |
| 26.02.2026 | CEO of World Economic Forum quits after Epstein ties come to light | ZURICH: The president and CEO of the World Economic Forum, Borge Brende, said on Thursday (Feb 26) he was stepping down, a few weeks after the forum launched an independent investigation into his relationship with late US sex offender Jeffr... |
| 26.02.2026 | BreezeBio Closes Series B Funding | BreezeBio, (fka as GenEdit), a San Francisco, CA-based biotechnology company developing genetic medicines, raised an undisclosed amount in Series B funding.
The round was led by Yuanta Investment and DSC Investment, with participation from ... |
| 25.02.2026 | These 4 charts show the scale of Novo Nordisk’s woes | Pricing pressure, fierce competition, and pipeline setbacks are all weighing on Novo Nordisk.
The Danish company is less diversified than current and future competitors, and increasingly exposed to the U.S. market, where drug prices are com... |
| 23.02.2026 | Katalysen Ventures Forges Ahead: Strategic Moves Define Q4 2025 and Future Growth | Katalysen Ventures closed Q4 2025 with strategic vigor. Core investments surged, now comprising most of its portfolio value. Multiple directed share issues strengthened capital and broadened its investor base. New B2B tech additions like S4... |
| 23.02.2026 | Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the fourth quarter and... |
